首页> 外文期刊>Theranostics >Multimodal Assessment of Mesenchymal Stem Cell Therapy for Diabetic Vascular Complications
【24h】

Multimodal Assessment of Mesenchymal Stem Cell Therapy for Diabetic Vascular Complications

机译:间充质干细胞疗法对糖尿病性血管并发症的多模式评估

获取原文
           

摘要

Peripheral arterial disease (PAD) is a debilitating complication of diabetes mellitus (DM) that leads to thousands of injuries, amputations, and deaths each year. The use of mesenchymal stem cells (MSCs) as a regenerative therapy holds the promise of regrowing injured vasculature, helping DM patients live healthier and longer lives. We report the use of muscle-derived MSCs to treat surgically-induced hindlimb ischemia in a mouse model of type 1 diabetes (DM-1). We serially evaluate several facets of the recovery process, including αVβ3 -integrin expression (a marker of angiogenesis), blood perfusion, and muscle function. We also perform microarray transcriptomics experiments to characterize the gene expression states of the MSC-treated is- chemic tissues, and compare the results with those of non-ischemic tissues, as well as ischemic tissues from a saline-treated control group.
机译:周围动脉疾病(PAD)是使糖尿病(DM)衰弱的并发症,每年导致成千上万的受伤,截肢和死亡。间充质干细胞(MSCs)作为再生疗法的使用有望使受伤的脉管系统重新生长,从而帮助DM患者生活得更健康,更长寿。我们报告了使用肌肉衍生的MSC在1型糖尿病(DM-1)小鼠模型中治疗由手术引起的后肢缺血。我们连续评估恢复过程的几个方面,包括α V β 3 -整联蛋白表达(血管生成的标志),血液灌注和肌肉功能。我们还进行了微阵列转录组学实验,以表征MSC治疗的缺血组织的基因表达状态,并将结果与​​非缺血组织以及生理盐水对照组的缺血组织进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号